Year All20242023202220212020201920182017201620152014 Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis March 10, 2022 Read More Abivax to host Satellite Symposium at the 17ᵗʰ Congress of ECCO on Feb. 17, 2022 February 08, 2022 Read More Abivax 2022 Financial Communication Calendar January 25, 2022 Read More Abivax phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21 at ASCO GI Cancers Symposium 2022 January 19, 2022 Read More Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis January 13, 2022 Read More Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference December 15, 2021 Read More Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis December 01, 2021 Read More Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022 November 30, 2021 Read More ABX464 shows excellent long-term efficacy data in Abivax’s phase 2b maintenance trial in ulcerative colitis October 18, 2021 Read More Abivax announces the release of its half-year financial report 2021 September 30, 2021 Read More
Abivax reports promising ABX464 phase 2a one-year maintenance results in rheumatoid arthritis March 10, 2022 Read More
Abivax to host Satellite Symposium at the 17ᵗʰ Congress of ECCO on Feb. 17, 2022 February 08, 2022 Read More
Abivax phase 1/2 clinical study results of ABX196 in liver cancer to be presented on Jan. 21 at ASCO GI Cancers Symposium 2022 January 19, 2022 Read More
Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis January 13, 2022 Read More
Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis December 01, 2021 Read More
Abivax’s phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium 2022 November 30, 2021 Read More
ABX464 shows excellent long-term efficacy data in Abivax’s phase 2b maintenance trial in ulcerative colitis October 18, 2021 Read More
